Lung cancer screening rates: Data from the lung cancer screening registry.

Pham, Danh; Bhandari, Shruti; Oechsli, Malgorzata; Pinkston, Christina; Kloecker, Goetz

doi:10.1200/jco.2018.36.15_suppl.6504

Cited by 73 publications

(50 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the proportion of deaths actually being addressed by recommended screening is likely much lower than one half, given that sizable proportions occur among unscreened persons (14). For example, in lung cancer, more than 70% of cases are diagnosed in persons not meeting USPSTF eligibility for lung screening (23) and utilization of screening among eligible persons remains below 5% (13,24). With over half of all cancer-related deaths not being addressed by existing guidelinebased screening, there remains large potential benefit of new approaches, especially those targeting multiple cancers.…”

Section: Discussionmentioning

confidence: 99%

Projected Reductions in Absolute Cancer–Related Deaths from Diagnosing Cancers Before Metastasis, 2006–2015

Clarke

Hubbell

Kurian

et al. 2020

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background: New technologies are being developed for early detection of multiple types of cancer simultaneously. To quantify the potential benefit, we estimated reductions in absolute cancerrelated deaths that could occur if cancers diagnosed after metastasis (stage IV) were instead diagnosed at earlier stages. Methods: We obtained stage-specific incidence and survival data from the Surveillance, Epidemiology, and End Results Program for 17 cancer types for all persons diagnosed ages 50 to 79 years in 18 geographic regions between 2006 and 2015. For a hypothetical cohort of 100,000 persons, we estimated cancer-related deaths under assumptions that cancers diagnosed at stage IV were diagnosed at earlier stages. Results: Stage IV cancers represented 18% of all estimated diagnoses but 48% of all estimated cancer-related deaths within 5 years. Assuming all stage IV cancers were diagnosed at stage III, 51 fewer cancer-related deaths would be expected per 100,000, a reduction of 15% of all cancer-related deaths. Assuming one third of metastatic cancers were diagnosed at stage III, one third diagnosed at stage II, and one third diagnosed at stage I, 81 fewer cancer-related deaths would be expected per 100,000, a reduction of 24% of all cancer-related deaths, corresponding to a reduction in allcause mortality comparable in magnitude to eliminating deaths due to cerebrovascular disease. Conclusions: Detection of multiple cancer types earlier than stage IV could reduce at least 15% of cancer-related deaths within 5 years, affecting not only cancer-specific but all-cause mortality. Impact: Detecting cancer before stage IV, including modest shifts to stage III, could offer substantial population benefit.

show abstract

Section: Discussionmentioning

confidence: 99%

Projected Reductions in Absolute Cancer–Related Deaths from Diagnosing Cancers Before Metastasis, 2006–2015

Clarke

Hubbell

Kurian

et al. 2020

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…Patients are often staged with advanced disease at time of diagnosis, thereby limiting curative treatment options. Although low-dose computed tomography is now a validated tool to screen patients and detect lung tumors at earlier stages, preliminary data suggests that screening has yet to be widely implemented, even among populations of higher socioeconomic status [3,4]. As such, for those at higher-risk for lung cancer who have not undergone routine screening, prompt evaluation of new respiratory symptoms is necessary to reduce the likelihood of locally-advanced or metastatic disease [5][6][7].…”

Section: Introductionmentioning

confidence: 99%

The time required to diagnose and treat lung cancer in Delhi, India: an updated experience of a public referral center

et al. 2019

View full text Add to dashboard Cite

Background: Delays that postpone the evaluation and management of malignancy may lead to considerable morbidity. The primary objective of this study was to assess the time required to diagnose and treat lung cancer at an Indian public referral center that predominantly serves lower-income patients. Methods: A review of patients diagnosed with lung cancer between January 2008 and December 2016 was completed. We computed the median time intervals and inter-quartile ranges between symptom onset, definitive diagnostic investigation, confirmed histologic diagnosis, and chemotherapy initiation. Median intervals were correlated with baseline demographics and disease characteristics using Kruskal-Wallis test. Results: One thousand, three hundred and-seventy patients were selected. A majority (94.5%) with non-small cell lung cancer were diagnosed with advanced disease. After developing symptoms, patients required 101 [56-168] days to undergo a definitive diagnostic study, 107 [60-173] days to confirm a diagnosis, and 126 [85-196.8] days to initiate treatment. Patients who were previously treated for tuberculosis required more time to receive chemotherapy compared to those who were not (187 [134-261.5] days vs. 113 [75-180] days, p < 0.0001). A specialty Lung Cancer Clinic was implemented in 2012, and the mean referrals per month increased nearly four-fold (p < 0.0001), but the time required to administer treatment was not shortened. Conclusion: Among lower-income Indian patients, the most prominent delays occur prior to diagnosis. Efforts should be directed toward encouraging physicians to maintain a high index of clinical suspicion and educating patients to report concerning symptoms as early as possible.

show abstract

“…Over 7million individuals are currently at risk in the United States for developing lung cancer, with 223,000 new cases reported annually with overall survival of approximately 18%. Yet, as of 2016 only 1.9% of high risk individuals were screened (4,19).…”

mentioning

confidence: 99%

Low Dose Lung CT Screening in an Asian Population

Naidich

2018

Academic Radiology

View full text Add to dashboard Cite

In the current edition of Academic Radiology, Hsu et al. (1) evaluate potential improvement in the detection of lesions in the spectrum of adenocarcinoma (LSAs) by first proposing modifications of current ACR Lung-RADS criteria and then retrospectively applying these to a screened cohort of Asian individuals including both ever and never-smokers, between 40 and 80years of age. The authors' contention is that by broadly expanding the number of eligible individuals for screening while simultaneously focusing on the most suspicious lesions, identifying adenocarcinomas will be significantly increased necessitating a reappraisal of current management guidelines. For this purpose, an Asian cohort of 1978 individuals (including 72.8% never-smokers), were retrospectively evaluated comparing criteria from the National Lung Screening Trial (NLST) (2) and ACR Lung-RADS to modified Lung-RADS criteria (3) as follows: Lung-RADS categories 2 and 3 were reclassified into subcategories 2A/B/C and 3A/B/C, respectively, with 2C defined as pure groundglass nodules <20mm, and 3B defined as part solid lesions ≥6mm with solid components >6mm, without altering morphologic characteristics (1). Using 2C as a cutoff then, modified Lung-RADS criteria proved to have greater predictive ability for identifying LSAs compared to either NLST or current Lung-RADS criteria (p < .001) with sensitivity of 100% (95% CI 89.1%, 100%), specificity of 89.3% (95% CI 87.9%, 90.6%) and an area under the curve (AUC) of 0.973 (95% CI 0.965-0.980), respectively. Similarly, using 3B as a cutoff resulted in an improved sensitivity of 95.0% (95% CI 75.1%, 99.9%), and specificity of 97.8% (95% CI 97.1%, 98.4%) for detecting invasive adenocarcinomas (IAs). While the AUC of .992, (95% CI 0.987-0.995) proved superior to the AUC using NLST criteria, however, no significant difference was noted comparing the current AUC of Lung-RADS to modified Lung-RADS criteria (p = .155).

show abstract

Lung cancer screening rates: Data from the lung cancer screening registry.

Cited by 73 publications

References 0 publications

Projected Reductions in Absolute Cancer–Related Deaths from Diagnosing Cancers Before Metastasis, 2006–2015

Projected Reductions in Absolute Cancer–Related Deaths from Diagnosing Cancers Before Metastasis, 2006–2015

The time required to diagnose and treat lung cancer in Delhi, India: an updated experience of a public referral center

Low Dose Lung CT Screening in an Asian Population

Contact Info

Product

Resources

About